Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
THOUSAND OAKS, Calif., July 30, 2013
-- Total revenues increased 5 percent to $4,679 million, with 9 percent product sales growth driven by Enbrel? (etanercept), Neulasta? (pegfilgrastim), XGEVA? (denosumab), and Prolia? (denosumab). Product sales included a positive adjustment of $185 million to previous estimates for managed Medicaid rebates based on recent claims experience. Other revenues were lower by $193 million as a result of a payment from Takeda recognized in the second quarter of 2012.
Hey, check out all the research scientist jobs. Post your resume today!
